Workshop on development of new antibacterial medicines

• Date:
  четвъртък, 25 October 2012, Цял ден
• Местоположение:
  European Medicines Agency, Amsterdam, the Netherlands

This workshop's aim is to discuss aspects of the development of antibacterial medicinal products, including those targeting multiple-drug-resistant pathogens and with narrow-action spectra and discussion on specific indications. Participation is invitation-based only.

Documents

Agenda – Workshop on development of new antibacterial medicines

Draft Reference Number: EMA/225314/2012

Report - Workshop on development of new antibacterial medicines

Reference Number: EMA/493109/2013

Presentation - Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) (Marco Cavaleri)

Presentation - 2012 addendum to the EU guideline on antibacterial agents (Mair Powell)

Presentation - Bridging the bench to bedside divide: Optimal dosing regimens of novel antimicrobials against multi drug resistant (MDR) pathogens (George Drusano)

Presentation - Antibiotic development for resistant bacteria: A Pharmacometric-based solution (Paul Ambrose)

Presentation - Superiority and organism-specific clinical trials of anitbacterial agents (Helen Boucher)

Presentation - Treatment of serious infections due to multiple drug resistant (MDR) acinetobacter baumannii: Presentation of a multicenter randomised clinical trial (Riccardo Utili)

Presentation - Drugs for multiple drug resistant (MDR) pathogens: Issues in development (Mark Goldberger)

Presentation - Issues to address for a Tier B development plan (Barry Eisenstein)

Presentation - Issues to address for a Tier C development (Aaron Dane)

Presentation - Considerations in the development of beta-lactamase inhibitor combination products for multiple drug resistant (MDR) pathogens (Michael Dudley)

Presentation - Challenges to develop diagnostics for treatment of multiple drug resistant (MDR) pathogens (Herman Goossens)

Presentation - Diagnostics: A focus on use in development of drugs for multiple drug resistant (MDR) pathogens (John Rex)

Presentation - Guidelines HAP/VAP: Standpoint from (some) academics (Serge Kouzan)

Presentation - HAP-VAP (David Friedland)

Presentation - Clinical trials in community-acquired pneumonia (CAP) (Francesco Blasi)

Presentation - Community-acquired pneumonia (CAP) (Keith Barker)

Presentation - Bacteraemia or severe sepsis as indication? (Bart Rijnders)

Presentation - Development of drugs for bacteremia (Charles Knirsch)

Presentation - Eradication of carriage (Jan Kluytmans)

Presentation - Development of drugs for eradication of nasal carriage of s. aureus to reduce s. aureus infections in vulnerable surgical patients (Richard Bax)

Presentation - Inhaled antibiotics in non-CF (Michael Loebinger)

Presentation - Inhalational antibacterial regimens in non-cystic fibrosis patients (Jeff Alder)